Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 149 of 1,261
  1. US 11851680

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  2. US 11850261

    Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

    Astellas Institute for Regenerative Medicine · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  3. US 11850259

    Methods of treating viral infections affecting the respiratory tract using topically administered lithium agents

    United States Government as represented by the Department of Veterans Affairs · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  4. US 11850228

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  5. US 11850227

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  6. US 11851443

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  7. US 11850226

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  8. US 11851498

    Anti-CD276 antibodies (B7H3)

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  9. US 11851490

    Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification

    Northwestern University · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  10. US 11850236

    Method for inhibiting Zika virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  11. US 11851440

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  12. US 11851479

    Methods and compositions for pertussis diagnosis

    DXDISCOVERY, INC. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  13. US 11851655

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  14. US 11850243

    Dihydropyridine compositions and methods for treating neurological disorders

    Cavalon Therapeutics, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  15. US 11850229

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  16. US 11850269

    Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

    Finch Therapeutics Holdings LLC · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  17. CA 3259417

    DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT LE RÉCEPTEUR DES LYMPHOCYTES T

    ABLYNX NV [BE] · Granted Dec 21, 2023 · Expires Dec 16, 2043

    granted
  18. US 11845990

    Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype

    VANDA PHARMACEUTICALS INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  19. US 11845937

    RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  20. US 11845963

    HSD17B13 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  21. US 11845957

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  22. US 11844841

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  23. US 11845965

    Regulation of gene expression using engineered nucleases

    Sangamo Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  24. US 11845727

    Aldehyde and ketone derivatives of psilocybin and methods of using

    Enveric Biosciences Canada Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.